Comprehensive SWOT analysis reveals Gilead Sciences Inc's strategic positioning in the pharmaceutical ... Gilead Sciences Inc ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

This analysis delves into the latest insights on Gilead Sciences. The consensus rating ... with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset ...

Decoding Analyst Ratings: A Detailed Look An in-depth analysis ... Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Presentation Operator Good afternoon, everyone, and welcome to Gilead's Third Quarter 2024 Earnings Conference Call. My name ...

Gilead Sciences (GILD) has been one of the most ... determined by the present value of its future stream of earnings. Our analysis is essentially based on how sell-side analysts covering the ...

Operator Good afternoon, everyone, and welcome to Gilead's third quarter 2024 earnings conference call. My name is Rebecca, and I'll be your host for today. In a moment, we'll begin with our prepared ...

The consensus rating for Gilead Sciences is Neutral, based on 16 analyst ratings. With an average one-year price target of $84.25, there's a potential 6.22% downside.